Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeat dosing of GSK3772847 in moderate to severe asthma with allergic fungal airway disease
2017-003544-20Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing GSK3772847 with Placebo (2 arms). Primary endpoint: Change from baseline in blood eosinophils over time. Started Dec 2017; status: completed.
02
Drugs
melrilimab
03
Conditions
asthma
Beyond the preview
Go deeper on 2017-003544-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003544-20.